Get the Daily Brief
Latest Biotech News
New Small‑Molecule and Immune Targets Disclosed — STAT6 and cGAS Inhibitors
Two disclosures revealed new small-molecule inhibitor programs from established organizations: Kymera Therapeutics reported discovery of STAT6 inhibitors aimed at oncology and inflammatory...
Aspen raises $115m: scales personalized Parkinson’s cell therapy
Aspen Neuroscience closed a $115 million Series C to advance ANPD001, its autologous iPSC-derived cell therapy for Parkinson’s disease and to scale manufacturing, clinical operations and pipeline...
FDA’s plausible mechanism pathway...rare-disease approvals debated
US regulatory officials published a 'plausible mechanism pathway' framework in The New England Journal of Medicine proposing an expedited approval route for bespoke medicines for ultra-rare...
U.K. budget boosts venture funding – lab costs rise for biotechs
The U.K. budget introduced measures to widen venture and share‑option flexibility aimed at supporting biotech fundraising, but simultaneously raised business rates that could increase operating...
CrisprBits bags $3m...investors push maturity to cross valley of death
Indian CRISPR diagnostics startup CrisprBits raised US$3 million in a Pre-Series A round led by Spectrum Impact to expand CRISPR-based diagnostics and R&D capabilities. The funding aims to...
Allogeneic cell therapies advance: iNKT cells and mRNA‑enhanced MSCs
A phase 1 trial tested allogeneic iPSC-derived invariant natural killer T (iNKT) cells in recurrent head and neck cancer, marking progress for off-the-shelf engineered immune cells. The study...
China clears JMT-206...GLP-1 drugs still pose unanswered safety and efficacy questions
CSPC gained China NMPA clearance to begin clinical trials of JMT-206 for weight management in people with obesity or overweight with comorbidities, moving a domestic candidate into clinical...
Senescent cell immunization: two reports propose tumor-targeting vaccine strategy
Ichim et al. published work in the Journal of Translational Medicine describing 'senescent cell immunization' as a novel approach to target solid tumors by directing immune responses against...
Mechanisms meet therapeutics: NEK7 biology and CAR-macrophages attack liver fibrosis
Two independent preclinical advances target liver fibrosis from complementary angles. A CAR‑macrophage therapy reduced fibrosis in mouse models, demonstrating that engineered macrophages can be...
Next‑gen oncology inhibitors: PRMT5 and TEAD programs show preclinical traction
Tango Therapeutics reported preclinical efficacy for TNG‑456, a selective, MTA‑cooperative PRMT5 inhibitor showing antitumor activity in glioma and metastasis-prone tumors. The compound targets...
WGS from FFPE: method unlocks archival tumor genomes
Researchers developed a robust workflow enabling whole-genome sequencing (WGS) from formalin-fixed paraffin-embedded (FFPE) tissue specimens, overcoming historical limitations of DNA damage and...
Aspen raises $115m Series C: scales iPSC Parkinson’s program
Aspen Neuroscience closed a $115 million Series C to accelerate clinical development of ANPD001 and expand manufacturing for autologous iPSC‑derived therapies. The company said proceeds will...
Vigencell’s lymphoma cell therapy meets phase II endpoint – regulatory move planned
Vigencell reported positive top‑line results from a Phase II study of VT‑EBV‑N, an antigen‑specific killer T‑cell therapy targeting NK/T‑cell lymphoma, and plans to seek conditional approval in...
CSPC cleared to start JMT‑206 obesity trials in China – NMPA gives green light
CSPC Pharmaceutical Group received clinical trial clearance from China’s National Medical Products Administration (NMPA) to test JMT‑206 for weight management in people with obesity or overweight...
Novo files high‑dose Wegovy with FDA – voucher to expedite review
Novo Nordisk submitted a higher‑dose formulation of Wegovy to the U.S. Food and Drug Administration, using an awarded voucher to speed the review timetable. The filing aims to broaden dosing...
Drug pricing shakeup: CMS cuts and MFN guidance reshape GLP‑1 economics
Two policy moves crystallized pricing pressure on high‑revenue drugs. CMS published negotiated prices under the Inflation Reduction Act that industry analysts say translate into larger net...
SK Biopharma in‑licenses WT‑7695: radiopharmaceutical rights inked
SK Biopharmaceuticals struck an exclusive worldwide license with the Wisconsin Alumni Research Foundation (WARF) to develop, manufacture and commercialize WT‑7695, a preclinical...
WGS from FFPE: robust method unlocks archival tumor genomes
Researchers published a validated workflow enabling robust whole‑genome sequencing (WGS) from formalin‑fixed, paraffin‑embedded (FFPE) tumor specimens, overcoming longstanding technical hurdles....
Allogeneic iPSC‑iNKT cells tested in head and neck cancer – early clinical signals
Investigators reported initial clinical testing of allogeneic induced pluripotent stem cell (iPSC)‑derived invariant natural killer T (iNKT) cells in recurrent head and neck cancer. The Phase I...
CrisprBits lands $3m pre‑Series A – expands CRISPR diagnostics and R&D
Indian biotech CrisprBits closed a US$3 million pre‑Series A round led by Spectrum Impact, the family office of Rajendra Gogri, to expand CRISPR‑based diagnostics and R&D capabilities. The funding...